News & Videos - SMITH & NEPHEW ORD USD0.20 - English - Page 2

First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December , the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the...

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared to traditional negative pressure wound therapy (tNPWT) in patients with lower extremity ulcers. 1* This press release features multimedia. View the full release here:...

UK’s NICE Publishes a Medtech Innovation Briefing on PICO™ for the Prophylactic Use in Surgically Closed Incisions to Reduce Surgical Site Complications PR Newswire LONDON and NEW YORK, July 3, 2018 LONDON and NEW YORK , July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of PICO Single Use Negative...